Sri Lanka

Sri Lanka

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.5 (1.34 - 1.66) 2019 Modelled IHME
1.56 (1.40 - 1.72) 2018 Modelled IHME
1.6 (1.43 - 1.78) 2017 Modelled IHME
1.62 (1.45 - 1.79) 2016 Modelled IHME
1.63 (1.47 - 1.81) 2015 Modelled IHME
1.66 (1.50 - 1.84) 2014 Modelled IHME
1.69 (1.52 - 1.87) 2013 Modelled IHME
1.73 (1.54 - 1.92) 2012 Modelled IHME
1.77 (1.57 - 1.97) 2011 Modelled IHME
1.81 (1.60 - 2.03) 2010 Modelled IHME
1.85 (1.63 - 2.08) 2009 Modelled IHME
1.9 (1.67 - 2.14) 2008 Modelled IHME
1.94 (1.70 - 2.20) 2007 Modelled IHME
1.98 (1.73 - 2.25) 2006 Modelled IHME
2.02 (1.75 - 2.30) 2005 Modelled IHME
2.05 (1.79 - 2.33) 2004 Modelled IHME
2.09 (1.83 - 2.38) 2003 Modelled IHME
2.12 (1.85 - 2.41) 2002 Modelled IHME
2.15 (1.86 - 2.44) 2001 Modelled IHME
2.17 (1.88 - 2.48) 2000 Modelled IHME
2.19 (1.89 - 2.50) 1999 Modelled IHME
2.2 (1.90 - 2.51) 1998 Modelled IHME
2.22 (1.91 - 2.52) 1997 Modelled IHME
2.23 (1.91 - 2.54) 1996 Modelled IHME
2.24 (1.91 - 2.56) 1995 Modelled IHME
2.26 (1.92 - 2.58) 1994 Modelled IHME
2.27 (1.92 - 2.60) 1993 Modelled IHME
2.29 (1.94 - 2.64) 1992 Modelled IHME
2.3 (1.95 - 2.67) 1991 Modelled IHME
2.32 (1.97 - 2.72) 1990 Modelled IHME
2.04 (1.47 - 2.78) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.07 (0.06 - 0.10) 2019 Modelled IHME
0.08 (0.06 - 0.10) 2018 Modelled IHME
0.08 (0.06 - 0.10) 2017 Modelled IHME
0.08 (0.06 - 0.10) 2016 Modelled IHME
0.08 (0.06 - 0.10) 2015 Modelled IHME
0.09 (0.07 - 0.11) 2014 Modelled IHME
0.09 (0.07 - 0.11) 2013 Modelled IHME
0.1 (0.07 - 0.12) 2012 Modelled IHME
0.1 (0.08 - 0.13) 2011 Modelled IHME
0.11 (0.08 - 0.14) 2010 Modelled IHME
0.12 (0.09 - 0.15) 2009 Modelled IHME
0.13 (0.10 - 0.17) 2008 Modelled IHME
0.15 (0.11 - 0.19) 2007 Modelled IHME
0.17 (0.13 - 0.22) 2006 Modelled IHME
0.21 (0.16 - 0.27) 2005 Modelled IHME
0.34 (0.26 - 0.44) 2004 Modelled IHME
0.63 (0.48 - 0.79) 2003 Modelled IHME
0.95 (0.73 - 1.20) 2002 Modelled IHME
1.24 (0.94 - 1.57) 2001 Modelled IHME
1.38 (1.02 - 1.77) 2000 Modelled IHME
1.41 (1.06 - 1.80) 1999 Modelled IHME
1.43 (1.08 - 1.84) 1998 Modelled IHME
1.45 (1.08 - 1.86) 1997 Modelled IHME
1.46 (1.09 - 1.89) 1996 Modelled IHME
1.48 (1.09 - 1.93) 1995 Modelled IHME
1.49 (1.12 - 1.94) 1994 Modelled IHME
1.51 (1.12 - 1.96) 1993 Modelled IHME
1.53 (1.13 - 1.97) 1992 Modelled IHME
1.54 (1.14 - 2) 1991 Modelled IHME
1.56 (1.16 - 2.05) 1990 Modelled IHME
0.64 (0.41 - 0.97) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
36 (27 - 46) 2019 Modelled IHME
36 (27 - 47) 2018 Modelled IHME
36 (27 - 47) 2017 Modelled IHME
37 (28 - 47) 2016 Modelled IHME
37 (28 - 48) 2015 Modelled IHME
38 (29 - 49) 2014 Modelled IHME
39 (29 - 49) 2013 Modelled IHME
40 (30 - 50) 2012 Modelled IHME
40 (31 - 51) 2011 Modelled IHME
41 (31 - 51) 2010 Modelled IHME
41 (32 - 51) 2009 Modelled IHME
41 (32 - 52) 2008 Modelled IHME
41 (32 - 52) 2007 Modelled IHME
41 (32 - 51) 2006 Modelled IHME
41 (32 - 51) 2005 Modelled IHME
42 (33 - 52) 2004 Modelled IHME
42 (33 - 52) 2003 Modelled IHME
42 (33 - 52) 2002 Modelled IHME
43 (34 - 53) 2001 Modelled IHME
43 (34 - 53) 2000 Modelled IHME
43 (34 - 53) 1999 Modelled IHME
43 (34 - 53) 1998 Modelled IHME
43 (34 - 53) 1997 Modelled IHME
43 (34 - 52) 1996 Modelled IHME
42 (34 - 52) 1995 Modelled IHME
42 (34 - 52) 1994 Modelled IHME
42 (34 - 53) 1993 Modelled IHME
42 (34 - 53) 1992 Modelled IHME
43 (34 - 53) 1991 Modelled IHME
43 (34 - 53) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
62 2004 Survey/reported WHO/UNICEF
32 2003 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.72 (0.58 - 0.88) 2019 Modelled IHME
0.72 (0.58 - 0.88) 2018 Modelled IHME
0.72 (0.58 - 0.88) 2017 Modelled IHME
0.71 (0.58 - 0.87) 2016 Modelled IHME
0.7 (0.57 - 0.85) 2015 Modelled IHME
0.71 (0.58 - 0.86) 2014 Modelled IHME
0.72 (0.59 - 0.87) 2013 Modelled IHME
0.73 (0.59 - 0.88) 2012 Modelled IHME
0.73 (0.60 - 0.89) 2011 Modelled IHME
0.74 (0.60 - 0.90) 2010 Modelled IHME
0.73 (0.59 - 0.88) 2009 Modelled IHME
0.69 (0.57 - 0.84) 2008 Modelled IHME
0.66 (0.54 - 0.80) 2007 Modelled IHME
0.63 (0.51 - 0.76) 2006 Modelled IHME
0.61 (0.50 - 0.75) 2005 Modelled IHME
0.62 (0.50 - 0.75) 2004 Modelled IHME
0.62 (0.51 - 0.75) 2003 Modelled IHME
0.63 (0.51 - 0.77) 2002 Modelled IHME
0.64 (0.52 - 0.79) 2001 Modelled IHME
0.66 (0.53 - 0.81) 2000 Modelled IHME
0.69 (0.56 - 0.85) 1999 Modelled IHME
0.74 (0.60 - 0.90) 1998 Modelled IHME
0.8 (0.64 - 0.97) 1997 Modelled IHME
0.84 (0.68 - 1.02) 1996 Modelled IHME
0.86 (0.70 - 1.05) 1995 Modelled IHME
0.86 (0.70 - 1.05) 1994 Modelled IHME
0.86 (0.69 - 1.04) 1993 Modelled IHME
0.86 (0.69 - 1.04) 1992 Modelled IHME
0.85 (0.69 - 1.04) 1991 Modelled IHME
0.84 (0.68 - 1.03) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
26 (18 - 34) 2019 Modelled IHME
26 (18 - 34) 2018 Modelled IHME
25 (17 - 33) 2017 Modelled IHME
25 (17 - 33) 2016 Modelled IHME
25 (17 - 33) 2015 Modelled IHME
25 (17 - 33) 2014 Modelled IHME
24 (17 - 32) 2013 Modelled IHME
24 (17 - 31) 2012 Modelled IHME
24 (16 - 31) 2011 Modelled IHME
23 (16 - 31) 2010 Modelled IHME
24 (16 - 31) 2009 Modelled IHME
23 (16 - 31) 2008 Modelled IHME
24 (17 - 31) 2007 Modelled IHME
24 (17 - 32) 2006 Modelled IHME
24 (17 - 31) 2005 Modelled IHME
24 (17 - 31) 2004 Modelled IHME
24 (17 - 31) 2003 Modelled IHME
24 (17 - 31) 2002 Modelled IHME
23 (16 - 31) 2001 Modelled IHME
23 (16 - 31) 2000 Modelled IHME
24 (16 - 31) 1999 Modelled IHME
24 (16 - 31) 1998 Modelled IHME
24 (17 - 31) 1997 Modelled IHME
24 (16 - 31) 1996 Modelled IHME
24 (17 - 31) 1995 Modelled IHME
24 (16 - 31) 1994 Modelled IHME
24 (17 - 32) 1993 Modelled IHME
24 (17 - 32) 1992 Modelled IHME
24 (17 - 32) 1991 Modelled IHME
24 (16 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.5 (%)
2019
(1.34 - 1.66(%))
IHME
HCV (RNA/cAg+)
0.72 (%)
2019
(0.58 - 0.88(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,274
2019
(879 - 1,797)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,481
2019
(1,002 - 2,089)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.07 (%)
2019, latest modelled
(0.06 - 0.10(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines